Cargando…

An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection

BACKGROUND: Selective prophylactic decontamination of the digestive tract is a strategy for the prevention of secondary nosocomial infection in patients with avian influenza virus subtype H7N9 infection. Our aim was to summarize the effectiveness of these therapies in re-establishing a stable and di...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Haifeng, Zhang, Chunxia, Qian, Guirong, Hu, Xinjun, Zhang, Hua, Chen, Chunlei, Liang, Weifeng, Gao, Hainv, Yang, Yunmei, Li, Lanjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107951/
https://www.ncbi.nlm.nih.gov/pubmed/24990477
http://dx.doi.org/10.1186/1471-2334-14-359
_version_ 1782327681450246144
author Lu, Haifeng
Zhang, Chunxia
Qian, Guirong
Hu, Xinjun
Zhang, Hua
Chen, Chunlei
Liang, Weifeng
Gao, Hainv
Yang, Yunmei
Li, Lanjuan
author_facet Lu, Haifeng
Zhang, Chunxia
Qian, Guirong
Hu, Xinjun
Zhang, Hua
Chen, Chunlei
Liang, Weifeng
Gao, Hainv
Yang, Yunmei
Li, Lanjuan
author_sort Lu, Haifeng
collection PubMed
description BACKGROUND: Selective prophylactic decontamination of the digestive tract is a strategy for the prevention of secondary nosocomial infection in patients with avian influenza virus subtype H7N9 infection. Our aim was to summarize the effectiveness of these therapies in re-establishing a stable and diverse microbial community, and reducing secondary infections. METHODS: Comprehensive therapies were dependent on the individual clinical situation of subjects, and were divided into antiviral treatment, microbiota-targeted therapies, including pro- or pre-biotics and antibiotic usage, and immunotherapy. Quantitative polymerase chain reaction and denaturing gradient gel electrophoresis (DGGE) were used for real-time monitoring of the predominant intestinal microbiome during treatment. Clinical information about secondary infection was confirmed by analyzing pathogens isolated from clinical specimens. RESULTS: Different antibiotics had similar effects on the gut microbiome, with a marked decrease and slow recovery of the Bifidobacterium population. Interestingly, most fecal microbial DGGE profiles showed the relative stability of communities under the continual suppression of the same antibiotics, and significant changes when new antibiotics were introduced. Moreover, we found no marked increase in C-reactive protein, and no cases of bacteremia or pneumonia, caused by probiotic use in the patients, which confirmed that the probiotics used in this study were safe for use in patients with H7N9 infection. Approximately 72% of those who subsequently suffered exogenous respiratory infection by Candida species or multidrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae were older than 60 years. The combination of probiotics and prebiotics with antibiotics seemed to fail in these patients. CONCLUSIONS: Elderly patients infected with the influenza A (H7N9) virus are considered a high-risk group for developing secondary bacterial infection. Microbiota restoration treatment reduced the incidence of enterogenous secondary infection, but not exogenous respiratory infection. The prophylactic effects of microbiota restoration strategies for secondary infection were unsatisfactory in elderly and critically ill patients.
format Online
Article
Text
id pubmed-4107951
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41079512014-07-24 An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection Lu, Haifeng Zhang, Chunxia Qian, Guirong Hu, Xinjun Zhang, Hua Chen, Chunlei Liang, Weifeng Gao, Hainv Yang, Yunmei Li, Lanjuan BMC Infect Dis Research Article BACKGROUND: Selective prophylactic decontamination of the digestive tract is a strategy for the prevention of secondary nosocomial infection in patients with avian influenza virus subtype H7N9 infection. Our aim was to summarize the effectiveness of these therapies in re-establishing a stable and diverse microbial community, and reducing secondary infections. METHODS: Comprehensive therapies were dependent on the individual clinical situation of subjects, and were divided into antiviral treatment, microbiota-targeted therapies, including pro- or pre-biotics and antibiotic usage, and immunotherapy. Quantitative polymerase chain reaction and denaturing gradient gel electrophoresis (DGGE) were used for real-time monitoring of the predominant intestinal microbiome during treatment. Clinical information about secondary infection was confirmed by analyzing pathogens isolated from clinical specimens. RESULTS: Different antibiotics had similar effects on the gut microbiome, with a marked decrease and slow recovery of the Bifidobacterium population. Interestingly, most fecal microbial DGGE profiles showed the relative stability of communities under the continual suppression of the same antibiotics, and significant changes when new antibiotics were introduced. Moreover, we found no marked increase in C-reactive protein, and no cases of bacteremia or pneumonia, caused by probiotic use in the patients, which confirmed that the probiotics used in this study were safe for use in patients with H7N9 infection. Approximately 72% of those who subsequently suffered exogenous respiratory infection by Candida species or multidrug-resistant Acinetobacter baumannii and Klebsiella pneumoniae were older than 60 years. The combination of probiotics and prebiotics with antibiotics seemed to fail in these patients. CONCLUSIONS: Elderly patients infected with the influenza A (H7N9) virus are considered a high-risk group for developing secondary bacterial infection. Microbiota restoration treatment reduced the incidence of enterogenous secondary infection, but not exogenous respiratory infection. The prophylactic effects of microbiota restoration strategies for secondary infection were unsatisfactory in elderly and critically ill patients. BioMed Central 2014-07-02 /pmc/articles/PMC4107951/ /pubmed/24990477 http://dx.doi.org/10.1186/1471-2334-14-359 Text en Copyright © 2014 Lu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research Article
Lu, Haifeng
Zhang, Chunxia
Qian, Guirong
Hu, Xinjun
Zhang, Hua
Chen, Chunlei
Liang, Weifeng
Gao, Hainv
Yang, Yunmei
Li, Lanjuan
An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection
title An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection
title_full An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection
title_fullStr An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection
title_full_unstemmed An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection
title_short An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection
title_sort analysis of microbiota-targeted therapies in patients with avian influenza virus subtype h7n9 infection
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107951/
https://www.ncbi.nlm.nih.gov/pubmed/24990477
http://dx.doi.org/10.1186/1471-2334-14-359
work_keys_str_mv AT luhaifeng ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT zhangchunxia ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT qianguirong ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT huxinjun ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT zhanghua ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT chenchunlei ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT liangweifeng ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT gaohainv ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT yangyunmei ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT lilanjuan ananalysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT luhaifeng analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT zhangchunxia analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT qianguirong analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT huxinjun analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT zhanghua analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT chenchunlei analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT liangweifeng analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT gaohainv analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT yangyunmei analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection
AT lilanjuan analysisofmicrobiotatargetedtherapiesinpatientswithavianinfluenzavirussubtypeh7n9infection